Janux Shares Are Trading Higher After It Announced Doses Selected for Its Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose.
Janux Shares Are Trading Higher After It Announced Doses Selected for Its Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose.
Janux股票在宣佈爲其10億擴展試驗選擇的劑量後交易上漲，支持這一選擇的有利療效和安全性特點在1a期劑量中得到了觀察。
Janux Shares Are Trading Higher After It Announced Doses Selected for Its Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose.
Janux股票在宣佈爲其10億擴展試驗選擇的劑量後交易上漲，支持這一選擇的有利療效和安全性特點在1a期劑量中得到了觀察。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間